D.H. Tang

Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.

To estimate adherence and persistence with etanercept plus methotrexate (ETN‐MTX) combination therapy and MTX, hydroxychloroquine, and sulfasalazine triple therapy at 1 year following treatment initiation in adults with rheumatoid arthritis (RA).

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis

To compare persistence and adherence to triple therapy with the nonbiologic disease‐modifying antirheumatic drugs (DMARDs) methotrexate (MTX), hydroxychloroquine, and sulfasalazine, versus a tumor necrosis factor inhibitor (TNFi) plus MTX in patients with rheumatoid arthritis (RA).

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

Abstract Objective: To determine annual biologic drug and administration costs to the US Veterans Health Administration (VHA) per treated patient with rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who received abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab, or ustekinumab. Methods: Adults with at least one biologic claim between January 1, 2008 and December 31, 2011 were included. Evidence of enrollment in the VHA was required from 365 days before (pre-index) to 360 days after (post-index) the date of the first biologic claim (index date). Included patients had pre-index diagnoses of RA, PsO, PsA, and/or AS. Drug costs were from Federal Supply Schedule or ‘Big Four’ in November 2014. Administration costs were VHA fixed costs for infused (

AB1109 A Retrospective Analysis on Predictors of Disease-Modifying Anti-Rheumatic Drug Initiation Among a Cohort of Patients with Newly Diagnosed Rheumatoid Arthritis

169) and subcutaneous (

THU0340 Prevalence of Joint Involvement and Frequency of Joint Exams for Patients with Plaque Psoriasis Without Confirmed Psoriatic Arthritis: An Analysis Across Five European Countries

25) biologics. Results: Of the 20,465 patients in the analysis, 10,711 received etanercept, 7838 received adalimumab, and 1196 received infliximab as the index biologic. In these patients, across all uses studied, the VHA incurred greater annual cost per treated patient for infliximab (

SAT0339 Comparative Effectiveness of First-Line Biologics Used for Rheumatoid Arthritis in a Managed Care Population

18,066) compared with adalimumab (

FRI0179 Comparative Effectiveness of Biologic Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis

16,523) and etanercept (

A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients

16,526). In the first year post-index, ∼80% of patients were either persistent on these index biologics or re-started these index biologics after a ≥45–day treatment gap. Other biologics comprised <5% of the study population, with sample sizes ranging from 3–374 patients each. Cost by indication for biologics used by >20 patients ranged from

Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study

15,056 (etanercept) to

Effectiveness and costs of biologics in veterans with rheumatoid arthritis

17,050 (abatacept) for RA;